09 May 2018 Research

Sharing this exciting news: a treatment advance for childhood leukaemia

A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades.

“We are excited at this breakthrough in the treatment for childhood leukaemia. CAR-T cell therapy gives those children who do not respond to chemotherapy treatment a real chance of a long-term cure. We welcome this significant step forward which will give hope to families whose children are affected by leukaemia.” 

Dr Maria Gilleece, Director, Yorkshire Blood and Marrow Transplant Programme and a member of the Leukaemia UK Medical Panel.

Follow this link to read this BBC news story.

Related posts

“Every little thing is gonna be alright” – three little birds tattoo marks mum’s recovery from one of the least survivable cancers

17 April 2024

“Every little thing is gonna be alright” – three little birds tattoo marks mum’s recovery from one of the least survivable cancers

New research by Leukaemia UK which could reduce the side-effects of treatment for acute myeloid leukaemia (AML) welcomed by family affected by the disease.   A family who was devastated when…

Emerging leaders accolade for former Leukaemia UK John Goldman Fellows

20 October 2023

Emerging leaders accolade for former Leukaemia UK John Goldman Fellows

Former Leukaemia UK John Goldman Fellows, Dr Matthew Blunt, University of Southampton and Dr Konstantinos Tzelepis, University of Cambridge have been recognised as ‘Emerging Leaders in Leukaemia’ by the major…

Leukaemia: Investigating stem cells to prevent cancer

11 January 2019

Leukaemia: Investigating stem cells to prevent cancer

Dr Alice Giustacchini, University College London and John Goldman Fellow

MP opens Leukaemia UK Ambulatory Care Unit

15 June 2018

MP opens Leukaemia UK Ambulatory Care Unit

A unit funded by Leukaemia UK which allows people with blood cancer to have stem cell transplants as out-patients has been officially opened by its first patient, Nick Boles MP